1991 - 2000 of 5662 Results
Title
Year
- Membrane‐destabilizing ionizable lipid empowered imaging‐guided siRNA delivery and cancer treatment2021OPENTitle: Membrane‐destabilizing ionizable lipid empowered imaging‐guided siRNA delivery and cancer treatmentJournal Name: ExplorationPublisher: WileyVol: 1Issue #: 1Start Page: 35End Page: 49Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1002/exp.20210008Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/EXP.20210008Citation Count: 96
- Mitochondrial oxidant stress mediates methamphetamine neurotoxicity in substantia nigra dopaminergic neurons2021OPENTitle: Mitochondrial oxidant stress mediates methamphetamine neurotoxicity in substantia nigra dopaminergic neuronsJournal Name: Neurobiology of DiseasePublisher: Elsevier BVVol: 156Issue #:Start Page: 105409End Page: 105409Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.nbd.2021.105409Best OA location URL: https://doi.org/10.1016/j.nbd.2021.105409Citation Count: 23
- Preformed fibrils generated from mouse alpha-synuclein produce more inclusion pathology in rats than fibrils generated from rat alpha-synuclein2021OPENTitle: Preformed fibrils generated from mouse alpha-synuclein produce more inclusion pathology in rats than fibrils generated from rat alpha-synucleinJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 89Issue #:Start Page: 41End Page: 47Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.06.010Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429263Citation Count: 9
- Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial2021OPENTitle: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trialJournal Name: Nature MedicinePublisher: Springer Science and Business Media LLCVol: 27Issue #: 8Start Page: 1451End Page: 1457Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1038/s41591-021-01455-xBest OA location URL: https://discovery.ucl.ac.uk/10134438/1/Dam%20%20%20%20PASSPORT%20Primary%20MS%20rev%20NMED-A110517A%20Final%20PIPE-18442%20w%20Figs.pdfCitation Count: 78
-
OPENTitle: Uremic Striatopallidal Syndrome Manifesting as Acute Onset ChoreaJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 8Issue #: S1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mdc3.13285Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.13285Citation Count: 2
-
OPENTitle: Use of Figurative Language by People With Parkinson Disease to Describe “Off” PeriodsJournal Name: Neurology Clinical PracticePublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 11Issue #: 4Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1212/cpj.0000000000001059Best OA location URL: https://cp.neurology.org/content/neurclinpract/11/4/e462.full.pdfCitation Count: 2
- Auditory and olfactory findings in patients with USH2A‐related retinal degeneration—Findings at baseline from the rate of progression in USH2A‐related retinal degeneration natural history study (RUSH2A)2021OPENTitle: Auditory and olfactory findings in patients with USH2A‐related retinal degeneration—Findings at baseline from the rate of progression in USH2A‐related retinal degeneration natural history study (RUSH2A)Journal Name: American Journal of Medical Genetics Part APublisher: WileyVol: 185Issue #: 12Start Page: 3717End Page: 3727Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/ajmg.a.62437Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717864Citation Count: 5
-
OPENTitle: Dream Content Predicts Motor and Cognitive Decline in Parkinson's DiseaseJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 8Issue #: 7Start Page: 1041End Page: 1051Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mdc3.13318Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.13318Citation Count: 9
- From structure to ætiology: a new window on the biology of leucine-rich repeat kinase 2 and Parkinson's disease2021OPENTitle: From structure to ætiology: a new window on the biology of leucine-rich repeat kinase 2 and Parkinson's diseaseJournal Name: Biochemical JournalPublisher: Portland Press Ltd.Vol: 478Issue #: 14Start Page: 2945End Page: 2951Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1042/bcj20210383Best OA location URL: https://portlandpress.com/biochemj/article-pdf/478/14/2945/918073/bcj-2021-0383.pdfCitation Count: 4
- Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change2021OPENTitle: Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of ChangeJournal Name: Movement DisordersPublisher: WileyVol: 36Issue #: 12Start Page: 2853End Page: 2861Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.28730Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688189Citation Count: 8